URGN
UROGEN PHARMA LTD
Latest close $39.92 as of Aug 4, 2026
Schedule 13G/13D reports beneficial ownership at an observation date. “Accumulation” or “reduction” is inferred
from changes in reported shares when available; it is not a list of individual trades or exact execution prices.
Form 13F rows are quarter-end holding context only and do not establish an exact entry date.
Free access includes current parsed ownership filings, reported share changes, and ownership-percentage changes.
Significance scoring, disclosure-speed analysis, confirmation/divergence signals, and signal alerts require Investor or Pro.
Compare plans.
Beneficial ownership filing history
Showing 3 of 4 parsed filing(s) · 1 older require more history access| Holder | Observed / filed | Reported change | Shares | Ownership | Observation | Filing | Latest |
|---|---|---|---|---|---|---|---|
| BlackRock CIK0002012383 | Mar 31, 2026 observed Apr 27, 2026 filed · 27d Initial Schedule 13G | Initial Schedule 13G | 2.5M | 12.00% | $17.98 | $23.77 | $39.92 |
| BlackRock CIK0002012383 | Sep 30, 2024 quarter end Nov 13, 2024 filed Form 13F quarter-end evidence | Earlier Form 13F quarter-end holding Quarter-end holding evidence; no ownership percentage or signal. | 2.5M | $39.92 | |||
| BlackRock Legacy CIK0001364742 | Apr 30, 2024 observed May 8, 2024 filed · 8d Schedule 13G amendment | Exit below reporting threshold | 1.7M -49.8K | 4.60% -1.00 pts | $13.27 | $39.92 |